| Report ID |
29459 |
| Drug Identification Number |
02347393 |
| Brand name |
MENVEO |
| Common or Proper name |
Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine |
| Company Name |
GLAXOSMITHKLINE INC |
| Market Status |
MARKETED |
| Active Ingredient(s) |
MENINGOCOCCAL GROUP C OLIGOSACCHARIDE
CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN
MENINGOCOCCAL GROUP A OLIGOSACCHARIDE
MENINGOCOCCAL GROUP Y OLIGOSACCHARIDE
MENINGOCOCCAL GROUP W-135 OLIGOSACCHARIDE |
| Strength(s) |
5MCG
47MCG
10MCG
5MCG
5MCG |
| Dosage form(s) |
SOLUTION
POWDER FOR SOLUTION |
| Route of administration |
INTRAMUSCULAR |
| Packaging size |
1 dose |
| ATC code |
J07AH |
| ATC description |
BACTERIAL VACCINES |
| Reason for shortage |
Delay in shipping of the drug. |
| Anticipated start date |
|
| Actual start date |
2017-12-06 |
| Estimated end date |
2018-01-18 |
| Actual end date |
2018-01-17 |
| Shortage status |
Resolved |
| Updated date |
2018-01-19 |
| Company comments |
Menveo 5 dose format still available. Supply disruptions may be seen in the private market. |
| Health Canada comments |
|
| Company contact information |
1-800-387-7374 |
